Digital PCR News and Research

RSS

Presence of tumor DNA in blood linked to poor outcomes in pancreatic cancer patients

The presence of circulating tumor DNA (ctDNA) isolated from blood samples of patients with pancreatic adenocarcinoma was associated with poor outcomes.

19 Dec 2016

New personalized DNA-based digital assay has potential to dramatically impact CML management

The outcomes of chronic myeloid leukemia (CML) have dramatically improved as the result of tyrosine kinase inhibitor (TKI) treatment. Use of a TKI regimen can lower the blood CML biomarker to levels imperceptible by current detection methods. For patients in "molecular remission," however, uncertainties remain regarding whether they will relapse or if treatment should be discontinued.

8 Feb 2016

New test predicts breast cancer relapse months in advance

UK-based researchers have developed a blood test that can predict whether patients with breast cancer will experience a relapse after receiving treatment, months before tumors are visible using hospital scans.

27 Aug 2015

Kalorama Information: Budding market for digital PCR reached 175 million in 2014

Kalorama Information estimated the budding market for digital PCR reached 175 million in 2014. The market research publisher said companies will be looking to provide products to increase research and diagnostics in diseases like cancer and neurological disorders.

13 Mar 2015

RNA molecules in tissue, urine samples can detect prostate cancer

Researchers at Sanford-Burnham Medical Research Institute have identified a set of RNA molecules that are detectable in tissue samples and urine of prostate cancer patients but not in normal healthy individuals.

10 Oct 2014

Agena Bioscience expands ultrasensitive somatic mutation detection technology

Agena Bioscience, Inc., which recently acquired the Bioscience business of Sequenom, Inc., today announced expansion of the UltraSEEK™ technology, the first ultrasensitive somatic mutation detection technology for high-throughput and definitive interrogation of rare mutations that occur at less than 1% abundance in matched tissue, circulating plasma, and tumor samples.

31 May 2014

Transgenomic signs license with Dana-Farber to develop multiplexed ICE COLD-PCR technology

Transgenomic, Inc., a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical and research services, today announced that it has signed a license with the Dana-Farber Cancer Institute for worldwide rights to develop and commercialize multiplexed versions of its ICE COLD-PCRTM technology (MX ICE COLD-PCR).

28 May 2014

Researchers demonstrate power of Droplet Digital PCR at 2014 AACR annual meeting

Helping doctors monitor their melanoma patients' progress in response to treatment is just one of the many exciting applications of Bio-Rad's Droplet Digital PCR (ddPCR-) technology being showcased at the 2014 American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, CA from April 5-9.

7 Apr 2014

Massachusetts Life Sciences Center provides $1.65M in capital grant to North Shore InnoVentures

North Shore InnoVentures, one of New England's leading technology incubators and business accelerators, announced today that it has received a capital grant of $1.65 million from the Massachusetts Life Sciences Center.

From Evident Corporation - Life Sciences 28 Mar 2014

RainDance Technologies closes $16.5 million Series E financing round

RainDance Technologies, Inc., an innovative genomics tools company making molecular testing of complex diseases more standardized and readily available, today announced that it has closed a $16.5 million Series E financing round extension. New investors include GE Ventures and Northgate Capital; all existing financial investors also participated in this round of financing.

3 Mar 2014

Scientists to highlight Bio-Rad's Droplet Digital PCR applications at CHI Digital PCR Conference

Since its introduction in 2011, Bio-Rad Laboratory's Droplet Digital PCR (ddPCR-) technology has demonstrated the potential to be a transformative technology, particularly in clinical applications.

8 Oct 2013

Study identifies new tool to accurately analyze mtDNA deletions associated with diseases, aging

A study published today in Aging Cell identifies a new tool to accurately analyze extremely rare mitochondrial DNA deletions associated with a range of diseases and disorders as well as aging. This approach, which relies on Droplet Digital PCR (ddPCR-) technology, will help researchers explore mtDNA deletions as potential disease biomarkers.

4 Sep 2013

ddPCR technology can be used to reproducibly quantify microRNA in plasma

A study published online in Nature Methods today demonstrated that Droplet Digital PCR (ddPCR-) technology can be used to precisely and reproducibly quantify microRNA (miRNA) in plasma and serum across different days, paving the way for further development of miRNA and other nucleic acids as circulating biomarkers.

2 Sep 2013

Researchers develop ddPCR technology to quantify rejection biomarker in organ transplant injury

A recently reported blood test for the early detection of organ transplant injury could enable more timely therapeutic intervention in transplant patients and thus help to avoid longer term damage. As described by scientists at the University Medical Center G-ttingen and Chronix Biomedical, a molecular diagnostics company, the new method uses Bio-Rad Laboratories' Droplet Digital PCR (ddPCR-) technology to overcome the obstacles of earlier tests, which were both time-consuming and costly.

28 Aug 2013

Novel potential biomarker present in CSF reveals signs of dementia decade before

A study published today reported the identification of what may be the earliest known biomarker associated with the risk of developing Alzheimer's disease (AD). The results suggest that this novel potential biomarker is present in cerebral spinal fluid (CSF) at least a decade before signs of dementia manifest.

16 Aug 2013

Trovagene adopts RainDance's RainDrop digital PCR system for eventual use in CLIA laboratory

Trovagene, Inc. (NASDAQ: TROV) and RainDance Technologies announced today that Trovagene has adopted RainDance's RainDropTM Digital PCR System for research and development, and for eventual use in the Trovagene CLIA laboratory.

29 Jul 2013

Digital versions of standard molecular biology tool to detect common tumor-associated mutation in CSF

Massachusetts General Hospital (MGH) researchers and their colleagues have used digital versions of a standard molecular biology tool to detect a common tumor-associated mutation in the cerebrospinal fluid (CSF) of patients with brain tumors. In their report being published in the open-access journal Molecular Therapy - Nucleic Acids, the investigators describe using advanced forms of the gene-amplification technology polymerase chain reaction (PCR) to analyze bits of RNA carried in membrane-covered sacs called extracellular vesicles for the presence of a tumor-associated mutation in a gene called IDH1.

24 Jul 2013

RainDance Technologies announces closing of $20M Series E financing round

RainDance Technologies, Inc., the Digital Biology Company, today announced the closing of a $20 million Series E financing round. The company also announced that Myriad Genetics, Inc. has joined as a new strategic equity investor.

29 Apr 2013

BEAMing technology detects more mutations linked with secondary drug resistance in GIST patients

A study presented at the AACR Annual Meeting 2013 indicates that a DNA blood test using Inostics' BEAMing Digital PCR can detect more mutations associated with secondary drug resistance in GIST patients than testing conventional biopsies.

9 Apr 2013

Blood test reveals more gene mutations in cancer than traditional tumor biopsy

A new blood test revealed more of the gene mutations that sustain certain digestive-tract tumors than did a DNA analysis of a traditional tumor biopsy, Dana-Farber Cancer Institute investigators will report at a special symposium of the American Association for Cancer Research annual meeting in Washington, April 6-10.

8 Apr 2013